Comparing Biopsy Needles for Prostate Cancer Detection
This study is comparing a new biopsy needle, called SureCore, to the standard needle (Bard) used during a transperineal prostate biopsy. A prostate biopsy is a procedure to remove small tissue samples from the prostate to check for cancer. The SureCore needle is designed to collect more tissue, which might help doctors better detect and understand prostate cancer. You may be able to join if you are a man over 18 years old who is having a prostate biopsy. The study aims to see if the SureCore needle helps diagnose more prostate cancers or provides a clearer picture of the cancer's grade. The current status of this study is unclear.
- Study design
- This study involves about 50 men and compares two different biopsy needles during a standard prostate biopsy procedure.
- What's involved
- You would undergo a standard prostate biopsy procedure, where the doctor will alternate between using the SureCore and standard Bard needles. The study will then follow your progress for up to one year after the biopsy.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from the prostate biopsy procedure through study completion, up to one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of patients diagnosed with prostate cancer and histological grade of cancer detectedFrom prostate biopsy procedure through study completion up to 1 year
The primary outcome will evaluate whether cancer is detected on final pathological analysis. This will include the grade of cancer, percentage of core involved, and compare between the two needles.